[go: up one dir, main page]

MX2016016400A - Formulaciones de oximetazolina estabilizadas y sus usos. - Google Patents

Formulaciones de oximetazolina estabilizadas y sus usos.

Info

Publication number
MX2016016400A
MX2016016400A MX2016016400A MX2016016400A MX2016016400A MX 2016016400 A MX2016016400 A MX 2016016400A MX 2016016400 A MX2016016400 A MX 2016016400A MX 2016016400 A MX2016016400 A MX 2016016400A MX 2016016400 A MX2016016400 A MX 2016016400A
Authority
MX
Mexico
Prior art keywords
stabilized
oxymetazoline
present
formulations
provides
Prior art date
Application number
MX2016016400A
Other languages
English (en)
Other versions
MX379253B (es
Inventor
Sarpotdar Pramod
Warner Kevin
Zhang Steven
Ahluwalia Gurpreet
Kuang Amy
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53546693&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016016400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2016016400A publication Critical patent/MX2016016400A/es
Publication of MX379253B publication Critical patent/MX379253B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención provee formulaciones en crema estabilizadas de oximetazolina y usos de estas. La presente invención también provee un método para tratar el eritema facial asociado a la rosácea que comprende la administración tópica una o más veces al día de una composición farmacéutica que comprende 0,5%, 1,0% o 1,5% de oximetazolina o una sal farmacéuticamente aceptable de esta como único ingrediente activo en el sitio del eritema en el rostro de un paciente que necesita dicho tratamiento.
MX2016016400A 2014-06-11 2015-06-11 Formulaciones de oximetazolina estabilizadas y sus usos. MX379253B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462010838P 2014-06-11 2014-06-11
US201462069624P 2014-10-28 2014-10-28
PCT/US2015/035420 WO2015191917A1 (en) 2014-06-11 2015-06-11 Stabilized oxymetazoline formulations and their uses

Publications (2)

Publication Number Publication Date
MX2016016400A true MX2016016400A (es) 2017-06-12
MX379253B MX379253B (es) 2025-03-11

Family

ID=53546693

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016016400A MX379253B (es) 2014-06-11 2015-06-11 Formulaciones de oximetazolina estabilizadas y sus usos.

Country Status (7)

Country Link
US (6) US9801857B2 (es)
EP (1) EP3154517B8 (es)
AU (1) AU2015274532B2 (es)
CA (1) CA2951725C (es)
ES (1) ES2796871T3 (es)
MX (1) MX379253B (es)
WO (1) WO2015191917A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225918A1 (en) 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
AU2015274532B2 (en) * 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
CN115006537A (zh) 2016-01-26 2022-09-06 利维申制药有限公司 α-肾上腺素能药剂的组合物和用途
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
CN113784712A (zh) 2019-05-01 2021-12-10 克雷西奥生物科技有限公司 治疗瘙痒的方法
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147275A (en) 1964-09-01 Nh-cha
EP1054469B1 (de) 1999-05-19 2002-10-16 Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.V. Vorrichtung und Verfahren zum Erwärmen von Bauteilen aus mikrowellenabsorbierendem Kunststoff
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6573301B1 (en) 2002-04-23 2003-06-03 Bradley Pharmaceuticals, Inc. Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) * 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
AU2006223754B2 (en) 2005-03-15 2008-11-06 Campina Nederland Holding B.V. Dermatologic use of milk proteins
BRPI0612705A2 (pt) 2005-06-29 2010-11-30 Dsm Ip Assets Bv composições tópicas compreendendo nanopartìculas de uma isoflavona
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
CA2703109C (en) 2007-11-16 2017-07-18 Vicept Therapeutics, Inc. Compositions and methods for treating purpura
PT2645993T (pt) * 2010-12-03 2017-03-03 Allergan Inc Composições de creme farmacêutico compreendendo oximetazolina
ES2742273T3 (es) 2011-02-15 2020-02-13 Aclaris Therapeutics Inc Composiciones de crema farmacéuticas de oximetazolina para tratar los síntomas de la rosácea
WO2013010032A1 (en) * 2011-07-14 2013-01-17 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
KR20140091543A (ko) * 2011-10-19 2014-07-21 갈데르마 소시에떼아노님 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
AU2015274532B2 (en) * 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses

Also Published As

Publication number Publication date
US9974773B2 (en) 2018-05-22
MX379253B (es) 2025-03-11
CA2951725C (en) 2022-06-07
AU2015274532B2 (en) 2020-06-11
EP3154517B8 (en) 2020-06-03
US20230346749A1 (en) 2023-11-02
US10751325B2 (en) 2020-08-25
US20210169855A1 (en) 2021-06-10
AU2015274532A1 (en) 2017-01-12
US20190365713A1 (en) 2019-12-05
US12350255B2 (en) 2025-07-08
ES2796871T3 (es) 2020-11-30
US20170151217A1 (en) 2017-06-01
EP3154517A1 (en) 2017-04-19
US11517560B2 (en) 2022-12-06
EP3154517B1 (en) 2020-04-22
WO2015191917A1 (en) 2015-12-17
US9801857B2 (en) 2017-10-31
US20150359781A1 (en) 2015-12-17
US20180263962A1 (en) 2018-09-20
US10335391B2 (en) 2019-07-02
NZ727233A (en) 2023-10-27
CA2951725A1 (en) 2015-12-17

Similar Documents

Publication Publication Date Title
CL2019003589A1 (es) Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer.
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CL2020000747A1 (es) Formulaciones de niraparib.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX377576B (es) Formulaciones de pridopidina de liberación modificada.
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2017013141A (es) Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo.
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
BR112018002530A2 (pt) combinações e usos e tratamentos destas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2019007555A (es) Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017010873A (es) Composiciones y métodos para el tratamiento de "placas y ovillos" en humanos y animales.
ZA201905309B (en) Pharmaceutical active ingredient and use thereof, in particular for the prevention and treatment of metabolic disorders in humans and animals
MX2017008879A (es) Composicion farmaceutica para el tratamiento de la micosis.
ECSP19024033A (es) Composiciones de tesofensina
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
CO2018005367A2 (es) Composición farmacéutica que contiene, como ingrediente activo, derivado de 7-azaindolin-2-ona o sal farmacéuticamente aceptable del mismo campo técnico
AR106220A1 (es) Conjugados homogéneos específicos de sitio con inhibidores de ksp
BR102016026256A8 (pt) composição farmacêutica e seus usos
WO2016115442A3 (en) Therapeutic protein formulations
AR101563A1 (es) Terapia de combinación de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano